Circulating levels of matrix metalloproteinase-9 and abdominal aortic pathology: From the Dallas Heart Study

Vascular Medicine

Volumn 16, Issue 5, 2011, Pages 339-345

  Grodin, Justin L ^a   Powell Wiley, Tiffany M ^b   Ayers, Colby R ^b   Kumar, Darpan S ^a   Rohatgi, Anand ^b   Khera, Amit ^b   McGuire, Darren K ^b   De Lemos, James A ^b   Das, Sandeep R ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

aortic aneurysm; aortic luminal diameter; aortic wall thickness; matrix metalloproteinase 9

Indexed keywords

GELATINASE B; PROTEINASE;

ABDOMINAL AORTA ANEURYSM; ADULT; ANEURYSM RUPTURE; AORTA ATHEROSCLEROSIS; ARTERIAL WALL THICKNESS; ARTICLE; BODY SIZE; CORONARY ARTERY; EXTRACELLULAR MATRIX; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AORTA, ABDOMINAL; AORTIC ANEURYSM, ABDOMINAL; COHORT STUDIES; CROSS-SECTIONAL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC; TEXAS; VASCULAR CALCIFICATION;

EID: 80054760669     PISSN: 1358863X     EISSN: 14770377     Source Type: Journal    
DOI: 10.1177/1358863X11422110     Document Type: Article

References (38)

1. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006 ; 69: 562-573 (Pubitemid 43139720)
2. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem. 2008 ; 54: 24-38 (Pubitemid 351182593)
3. Watanabe T, Sato A, Sawai T, et al. The elevated level of circulating matrix metalloproteinase-9 in patients with abdominal aortic aneurysms decreased to levels equal to those of healthy controls after an aortic repair. Ann Vasc Surg. 2006 ; 20: 317-321
4. Takagi H, Manabe H, Kawai N, Goto SN, Umemoto T. Circulating matrix metalloproteinase-9 concentrations and abdominal aortic aneurysm presence: a meta-analysis. Interact Cardiovasc Thorac Surg. 2009 ; 9: 437-440
5. Kai H, Ikeda H, Yasukawa H, et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol. 1998 ; 32: 368-372 (Pubitemid 28396484)
6. Zeng B, Prasan A, Fung KC, et al. Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease. Intern Med J. 2005 ; 35: 331-335 (Pubitemid 40826856)
7. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ, Kaski JC. High serum matrix metalloproteinase-9 level predict increased risk of in-hospital cardiac events in patients with type 2 diabetes and ST segment elevation myocardial infarction. Atherosclerosis. 2008 ; 196: 365-371
8. Victor RG, Haley RW, Willett DL, et al. The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. Am J Cardiol. 2004 ; 93: 1473-1480 (Pubitemid 38749202)
9. Jaffer FA, O'Donnell CJ, Larson MG, et al. Age and sex distribution of subclinical aortic atherosclerosis: a magnetic resonance imaging examination of the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2002 ; 22: 849-854 (Pubitemid 34517800)
10. Rosero EB, Peshock RM, Khera A, Clagett GP, Lo H, Timaran C. Agreement between methods of measurement of mean aortic wall thickness by MRI. J Magn Reson Imaging. 2009 ; 29: 576-582
11. Maroules CD, McColl R, Khera A, Peshock RM. Assessment and reproducibility of aortic atherosclerosis magnetic resonance imaging: impact of 3-Tesla field strength and parallel imaging. Invest Radiol. 2008 ; 43: 656-662
12. Jain T, Peshock R, McGuire DK, et al. African Americans and Caucasians have a similar prevalence of coronary calcium in the Dallas Heart Study. J Am Coll Cardiol. 2004 ; 44: 1011-1017 (Pubitemid 39165135)
13. Lund AK, Lucero J, Lucas S, et al. Vehicular emissions induce vascular MMP-9 expression and activity associated with endothelin-1-mediated pathways. Arterioscler Thromb Vasc Biol. 2009 ; 29: 511-517
14. Freestone T, Turner RJ, Coady A, Higman DJ, Greenhalgh RM, Powell JT. Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 1995 ; 15: 1145-1151
15. Wilson WR, Anderton M, Schwalbe EC, et al. Matrix metalloproteinase-8 and -9 are increased at the site of abdominal aortic aneurysm rupture. Circulation. 2006 ; 113: 438-445 (Pubitemid 43803206)
16. Sundstrom J, Evans JC, Benjamin EJ, et al. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation. 2004 ; 109: 2850-2856 (Pubitemid 38786446)
17. Fujimoto S, Hartung D, Ohshima S, et al. Molecular imaging of matrix metalloproteinase in atherosclerotic lesions: resolution with dietary modification and statin therapy. J Am Coll Cardiol. 2008 ; 52: 1847-1857
18. Massaro M, Zampolli A, Scoditti E, et al. Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: anti-angiogenic actions possibly contributing to plaque stability. Cardiovasc Res. 2010 ; 86: 311-320
19. Onal IK, Altun B, Onal ED, Kirkpantur A, Gul Oz S, Turgan C. Serum levels of MMP-9 and TIMP-1 in primary hypertension and effect of antihypertensive treatment. Eur J Intern Med. 2009 ; 20: 369-372
20. Zervoudaki A, Economou E, Stefanadis C, et al. Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment. J Hum Hypertens. 2003 ; 17: 119-124 (Pubitemid 36292367)
21. Lacchini R, Metzger IF, Luizon M, Ishizawa M, Tanus-Santos JE. Interethnic differences in the distribution of matrix metalloproteinases genetic polymorphisms are consistent with interethnic differences in disease prevalence. DNA Cell Biol. 2010 ; 29: 649-655
22. Fukuda D, Shimada K, Tanaka A, et al. Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris. Am J Cardiol. 2006 ; 97: 175-180 (Pubitemid 43139231)
23. Gurbel PA, Kreutz RP, Bliden KP, DiChiara J, Tantry US. Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease: a potential approach to identify atherosclerotic disease progression. Am Heart J. 2008 ; 155: 56-61 (Pubitemid 350234773)
24. Noji Y, Kajinami K, Kawashiri MA, et al. Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. Clin Chem Lab Med. 2001 ; 39: 380-384 (Pubitemid 32529917)
25. Tayebjee MH, Lip GY, Tan KT, Patel JV, Hughes EA, MacFadyen RJ. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease. Am J Cardiol. 2005 ; 96: 339-345 (Pubitemid 41058855)
26. Malayeri AA, Natori S, Bahrami H, et al. Relation of aortic wall thickness and distensibility to cardiovascular risk factors (from the Multi-Ethnic Study of Atherosclerosis [MESA]). Am J Cardiol. 2008 ; 102: 491-496
27. Heitner JF, Bhumireddy GP, Cawley PJ, et al. The aorta wall of patients presenting to the emergency department with acute myocardial infarction by cardiac magnetic resonance. Atherosclerosis. 2010 ; 212: 166-170
28. Jeltsch M, Klass O, Klein S, et al. Aortic wall thickness assessed by multidetector computed tomography as a predictor of coronary atherosclerosis. Int J Cardiovasc Imaging. 2009 ; 25: 209-217
29. Thompson RW, Holmes DR, Mertens RA, et al. Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms. An elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. J Clin Invest. 1995 ; 96: 318-326
30. Vallabhaneni SR, Gilling-Smith GL, How TV, Carter SD, Brennan JA, Harris PL. Heterogeneity of tensile strength and matrix metalloproteinase activity in the wall of abdominal aortic aneurysms. J Endovasc Ther. 2004 ; 11: 494-502 (Pubitemid 39096347)
31. Johnsen SH, Forsdahl SH, Singh K, Jacobsen BK. Atherosclerosis in abdominal aortic aneurysms: a causal event or a process running in parallel? The Tromso study. Arterioscler Thromb Vasc Biol. 2010 ; 30: 1263-1268
32. Aziz F, Kuivaniemi H. Role of matrix metalloproteinase inhibitors in preventing abdominal aortic aneurysm. Ann Vasc Surg. 2007 ; 21: 392-401 (Pubitemid 46678660)
33. Abdul-Hussien H, Hanemaaijer R, Verheijen JH, van Bockel JH, Geelkerken RH, Lindeman JH. Doxycycline therapy for abdominal aneurysm: improved proteolytic balance through reduced neutrophil content. J Vasc Surg. 2009 ; 49: 741-749
34. Zhang F, Kent KC, Yamanouchi D, et al. Anti-receptor for advanced glycation end products therapies as novel treatment for abdominal aortic aneurysm. Ann Surg. 2009 ; 250: 416-423
35. Vinh A, Gaspari TA, Liu HB, Dousha LF, Widdop RE, Dear AE. A novel histone deacetylase inhibitor reduces abdominal aortic aneurysm formation in angiotensin II-infused apolipoprotein E-deficient mice. J Vasc Res. 2008 ; 45: 143-152 (Pubitemid 351651300)
36. Xiao H, Bai XH, Kapus A, Lu WY, Mak AS, Liu M. The protein kinase C cascade regulates recruitment of matrix metalloprotease 9 to podosomes and its release and activation. Mol Cell Biol. 2010 ; 30: 5545-5561
37. Alsac JM, Journe C, Louedec L, et al. Downregulation of remodelling enzymatic activity induced by an angiotensin-converting enzyme inhibitor (perindopril) reduces the degeneration of experimental abdominal aortic aneurysms in a rat model. Eur J Vasc Endovasc Surg. 2011 ; 41: 474-480
38. Kent KC, Zwolak RM, Egorova NN, et al. Analysis of risk factors for abdominal aortic aneurysm in a cohort of more than 3 million individuals. J Vasc Surg. 2010 ; 52: 539-548